Skip to main content
ATHE
NASDAQ Life Sciences

Alterity Therapeutics Issues 18M Options, Signaling Near 100% Potential Dilution

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$3.4
Mkt Cap
$61.757M
52W Low
$2.521
52W High
$7
52W Position info
35% above low
Off High info
51% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

ATHE sits 35% above its 52-week low of $2.521 on light trading volume (0.3× avg).

Summary

Alterity Therapeutics has issued 18 million unlisted options under an employee incentive scheme, which, if exercised, could nearly double the company's US-equivalent shares outstanding, leading to substantial dilution for existing shareholders.


Key Events · Financing and Capital Events · ATHE

  • Issuance of Unlisted Options

    Alterity Therapeutics issued 18,000,000 unlisted options on January 15, 2026.

  • Employee Incentive Scheme

    The options were granted under an employee incentive scheme, not directly to key management personnel.

  • Significant Potential Dilution

    If exercised, these options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price.

  • Deeply In-The-Money Options

    The options have an exercise price of AUD 0.008 and expire in 2031, making them deeply in-the-money compared to the current US stock price of $3.40.


Analysis · ATHE · Life Sciences

Alterity Therapeutics has issued a substantial number of unlisted options under an employee incentive scheme. While not directly granted to key management personnel, the 18 million options represent a potential increase of nearly 100% in the company's US-equivalent shares outstanding, based on the current market capitalization and stock price. This level of potential dilution is highly significant and could materially impact the value of existing shares. The options' deeply in-the-money exercise price of AUD 0.008, compared to the current US stock price of $3.4, makes their eventual exercise highly probable, posing a considerable overhang on the stock.

At the time of this filing, ATHE was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $61.8M. The 52-week trading range was $2.52 to $7.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATHE - Latest Insights

ATHE
Jun 30, 2026, 6:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.92
Real-time Price: $4.59 info
Change: -$0.330 (-7%) info
Market Cap: $84.918M info
ATHE
Jun 17, 2026, 6:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.81
Real-time Price: $4.59 info
Change: -$0.220 (-5%) info
Market Cap: $84.918M info
ATHE
Jun 16, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.44
Real-time Price: $4.59 info
Change: +$0.150 (+3%) info
Market Cap: $84.918M info
ATHE
Jun 15, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.21
Real-time Price: $4.59 info
Change: +$0.380 (+9%) info
Market Cap: $84.918M info
ATHE
Jun 12, 2026, 6:07 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $4.59 info
Change: +$0.590 (+15%) info
Market Cap: $84.918M info